

16.1.2 Sample Case Report Form (Unique Pages Only)

This section contains the following document:

[Sample case report form version 1.0, dated 04 March 2020](#)

Birth Control (BC1)

We Ve s 2 00 04Ma 20

s the subject o s m e s o ch b e a i n g p o t e n t i a l o s e l i s m e s ?
 I No s e s s o n
 I O t h e r s p e c i f y
 I No d e s o M s u p e y o d a g n o s i s

☐ No ☐ es

es m e n s t r u a l c y c l e o >= y e s
 l a t e s t g a i n
 B e a e a t o p h o s c o p y
 B e a e a t o p h o s c o p y
 E s s u e
 * A d d i t i o n a l O p t i o n s s t e d B e l o w

Exact date
 Day on y unknown
 Day and month unknown
 Day month and year unknown

dsMMMyyyy

Me	Me	Me	Me	Me	Me	Me
Me change n me hod	Me change n me hod	Me change n me hod	Me change n me hod	Me change n me hod	Me change n me hod	Me change n me hod
0 at cont accept was 2 No moral injections 3 No moral injection s 4 Cont. acceptive pa ches 5 Nuavalling * A d d i t i o n a l O p t i o n s s t e d B e l o w	0 at cont accept was 2 No moral injections 3 No moral injection s 4 Cont. acceptive pa ches 5 Nuavalling * A d d i t i o n a l O p t i o n s s t e d B e l o w	0 at cont accept was 2 No moral injections 3 No moral injection s 4 Cont. acceptive pa ches 5 Nuavalling * A d d i t i o n a l O p t i o n s s t e d B e l o w	0 at cont accept was 2 No moral injections 3 No moral injection s 4 Cont. acceptive pa ches 5 Nuavalling * A d d i t i o n a l O p t i o n s s t e d B e l o w	0 at cont accept was 2 No moral injections 3 No moral injection s 4 Cont. acceptive pa ches 5 Nuavalling * A d d i t i o n a l O p t i o n s s t e d B e l o w	0 at cont accept was 2 No moral injections 3 No moral injection s 4 Cont. acceptive pa ches 5 Nuavalling * A d d i t i o n a l O p t i o n s s t e d B e l o w	0 at cont accept was 2 No moral injections 3 No moral injection s 4 Cont. acceptive pa ches 5 Nuavalling * A d d i t i o n a l O p t i o n s s t e d B e l o w

Additional Selection Options for BC1

If No reason
Vasectomy
Bilateral orchiectomy
Other
Method of birth control 1
6 - Intrauterine device, hormonal
7 - Intrauterine device, non-hormonal
8 - Barrier method plus spermicide
9 - Barrier method (a one)
10 - Spermicide (a one)
11 - Same-sex relationship
12 - Monogamous relationship with vasectomized partner
13 - Abstinence
99 - Other

Concomitant Medication (CMD)

We Ve s 20 May20

me A
me e

Medication
Start date

End date

Indication
Was this medication taken on an Adverse Event?
Is this medication AE

Was this medication taken on a condition listed on the Medical History?
Is this condition

Exact date Day only unknown Day and month unknown Day month and year unknown	
ddMM/yyyy	
Exact date Day only unknown Day and month unknown Day month and year unknown	
ddMM/yyyy	
☐ Ongoing	
☐ No ☐ Yes Selected AE	☐ Yes Unselected AE
Additional Options listed below	
Additional Options listed below	
Additional Options listed below	

Additional Selection Options for CMD

CMI Number (Key Field)

1
2
3

5
6
7
8
9
10
11
12
13
1
15
16
17
18
19
20
21
22
23
2
25
26
27
28
29
30
31
32
33
3
35
36
37
38
39
0
1
2
3

5
6
7
8
9
50

Consent Agreement (CS1)

Wk Vs s 2 02 0 u02

A

Do e n o med consent signed
I e consented date o e consent
Comments

	01/01/2022
	01/01/2022

Demographics (DEM)

We View 00 09/01/20

Sex Birth date Ethnicity	☐ Male ☐ Female ddMM/yyyy ☐ Hispanic or Latino ☐ Not Hispanic or Latino ☐ Not specified ☐ Unknown ☐ No ☐ Yes ☐ No ☐ Yes ☐ No ☐ Yes ☐ No ☐ Yes ☐ No ☐ Yes ☐ UNKNOWN ☐ AMERICAN INDIAN OR ALASKA NATIVE ☐ ASIAN ☐ NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER ☐ "Add Other Options" listed below
---	--

Additional Selection Options for DEM

Race
BLACK
WHITE

Study Status (DS1)

4.0 27Apr 20

A

Study status

Disco p. stocod comp e ion to mtrition
I se ty e m rati on Ind ca e e asion

I eason equl ee speci cation
AE number

DV number

E ighti y c ite on
C ite ion number

stocod completed

Se ty e mtrition

dsMMMyyyj

Se stus adve se event (o he "han death) speci y AE #

Adve se event o he "han se adve se event speci y AE #

stocod day at on speci y DV #

Volunte y e'te' used by subiect speci y

*Additional Options listed Below

2

3

4

5

*Additional Options listed Below

2

3

4

5

*Additional Options listed Below

☒ Inclusion ☐ Exclusion

2

3

4

5

*Additional Options listed Below

Additional Selection Options for DS1

If early termination indicate reason

Withdrawal by investigator, specify

COVID-19 pandemic, specify

Termination of site by sponsor

Termination of study by sponsor

Death, specify AE #

Enrolled but treatment not administered, specify

Pregnancy

Not eligible at enrollment, specify and enter eligibility criterion #

Became ineligible after enrollment, specify and enter eligibility criterion #

Discontinued event, specify

Other, specify

AE number

6

7

8

9

10

11

12

13

1

15

16

17

18

19

20

21

22

23

2

25

26

27

28

29

30

31

32

33

3

35

36

37

38

39

0

1

2

3

5

6

7

8

9

50

Criterion number

6

7

8

9

10

11

12

13

1

15

16

17

18

19

20

21

22

23

2

25

26

27

28

29

30

Discontinuation of Treatment (DS2)

• me •

Complete this on subject's discontinued study product
Date of discontinuation
Reason of discontinuation

1. Reason: equipment specification
AE number

DV number

Eligible citation
Citation number

Will the subject eman in he study o olow-up?
No subm a Study Saus om

@BMM[yyyy]

If you advance an event (to the next death) specify y AE #
 Advance an event (to h) then set your advance to event spent y AE #

Wait x time out
☐ dohold devat on speed y DV #
 "Advance my test by x seconds by advancing speed y"

*Add tonal Options listed Below

2
3
4
5
*Add tonal Options listed Below *

2
3
4
5
*Add tonal Options listed Below *

☐ Inclusion ☒ Exclusion

*Add tonal Options listed Below *

☐ No ☒ Yes

Additional Selection Options for DS2

Reason for discontinuation

Withdrawal by investigator or, specify

COVID-19 pandemic, specify

Termination of site by sponsor

Termination of study by sponsor

Death, specify AE #

Technical problems, specify

Pregnancy

Not eligible at enrollment, specify and enter eligibility criterion #

Became ineligible after enrollment, specify and enter eligibility criterion #

Discontinued event, specify

Other, specify

AE number

6

7

8

9

10

11

12

13

1

15

16

17

18

19

20

21

22

23

2

25

26

27

28

29

30

31

32

33

3

35

36

37

38

39

0

1

2

3

5

6

7

8

9

50

Criterion number

6

7

8

9

10

11

12

13

1

15

16

17

18

19

20

21

22

23

2

25

26

27

28

29

30

We Visited 3/03, 27Apr, 2003

652 10.9

total deviation

1 Other specify

Specimen type

Result type

Description

A. an. 0151 number

Gen. & date

1000

Reason: on school day(s)

1. Other specify _____

Did the deviation result in subject elimination or study follow-up?

Does the deviation affect conclusions?

Definition 2.1. Let $\mathcal{A}$ be a $\mathcal{C}^*$ -algebra and let $\mathcal{K}$ be a $\mathcal{C}^*$ -algebra. A $\mathcal{C}^*$ -algebra $\mathcal{B}$ is called a $\mathcal{C}^*$ -algebra over $\mathcal{A}$ if $\mathcal{B}$ is a $\mathcal{C}^*$ -algebra and $\mathcal{B}$ is a $\mathcal{C}^*$ -algebra over $\mathcal{A}$.

Is this day a lion an "Unannounced" job em?

Describe steps taken to resolve or avoid recurrence of the deviation

Does this deviation meet IRR, equipment, equipment?

1. as data IPB not led

Comments:

☐ Out o window v r t
☐ Inoo ect we sense v IC s grad
☐ Iplee men ess i not obdained
☐ Please ad p ovide e not conduct ed
☐ Please ad p ovide e done not acty

*Add tional Options isted Below *

☐ _____
☐ _____
☐ _____

☐ _____ dMMMMyyyyy
☐ _____ dMMMMyyyyy

☒ Ric e o
☐ ha may e o
☐ also abo y e o
☐ invest gals study decision
☐ COV D 3 parametric

*Add tional Options isted Below *

☐ No ☐ es ☐ NA

☐ If sply by n different
 estment adm n st ation sochedule
 of thw up v x t schedule
 ifloof c oodk a fundement
 estment adm n st ation

☐ No ☐ es

☐ No ☐ es ☐ NA

☐ _____ dMMMMyyyyy

Additional Selection Options for DV2

Dev ation Number (key file d)

- 1
- 2
- 3
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 1
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 2
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 3
- 35
- 36
- 37
- 38
- 39
- 0
- 1
- 2
- 3
- 5
- 6
- 7
- 8
- 9
- 50
- Protocol deviation
- Study product temperature excurs on
- Specimen temperature excurs on
- Other
- Reason for protocol deviation
- Other

We Ve s 3 02 27Apr 26

FDA-CBER-2022-1614-3223500

Additional Selection Options for DVD

Deviation Number (key file d)

1
2
3

5
6
7
8
9

10
11
12
13
14

15
16
17
18
19

20
21
22
23
24

25
26
27
28
29

30
31
32
33
34

35
36
37
38
39

0
1
2
3

5
6
7
8
9

50

Protocol deviation

ICF not signed prior to study procedures
Miscalculation of treatment administration
Delayed treatment administration
Blood not collected
Urine not collected
Too few aliquots obtained
Specimen result not obtained
Required procedure not conducted
Required procedure done incorrectly
Study product temperature excursion
Specimen temperature excursion
Other

Reason for protocol deviation

Laboratory error
Investigator/study decision
Other
COVID-19 pandemic

Specify so listed AE

Fatigue
Myalgia
Arthralgia
Nausea
Fever
Chills
WBC
Hemoglobin
Platelets
ALT
AST
ALP
Bilirubin (total)
Creatinine
PT
PTT

Registration Confirmation (ERC)

Wb Vb s 0 22Nov 6

me A

Adv grant
Regist a ion date
Regist a ion time
Regist a ion by

Sub-act ID
Enrollment date
Does the subject meet all eligibility criteria as specified in the current version of the protocol?
he subject does not meet a eligibility criteria specified which criteria have not been met
C to not meet

C to not meet 2

C to not meet 3

C to not meet 4

20003A (ENR)

0

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

0

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

0

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

0

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

0

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

0

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

0

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

0

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

Additional Selection Options for ENR

Criterion not met 1

Body Mass Index: 18-35 kg/m2 inclusive, at screening.

BMI: 18-35 kg/m2 inclusive or < 56 years of age; 18-30 kg/m2 inclusive for >= 56 years of age

Women of childbearing potential must agree to use at least one form of contraception.

Women of childbearing potential must have a negative pregnancy test prior to vaccination.

Male subjects of childbearing potential use an effective form of contraception.

Male subjects agree to refrain from sperm donation until 3 months after last study vaccination.

Male subjects agree to refrain from sperm donation until 60 days after last study vaccination.

In good health

Oral temperature less than 100.0°F (37.8°C).

Pulse no greater than 100 beats per minute.

Systolic blood pressure within the protocol eligibility criteria.

Systolic BP ≤ 85 or 150 mm Hg, inclusive

Screening laboratory evaluations are within acceptable normal ranges

Must agree to have samples stored for secondary research

Agrees to adhere to Lifestyle Considerations throughout study duration.

The subject must agree to refrain from donating blood or plasma during the study

Positive pregnancy test either at screening or just prior to each vaccine administration.

Female subject who is breastfeeding from the time of first vaccine through 60 days of last vaccination.

Has any medical disease or condition that precludes study participation.

Presence of self-reported or medically documented medical or psychiatric condition

Has an acute illness within 72 hours prior to each vaccination.

Has a positive test for Hepatitis B, Hepatitis C or HIV antibodies at screening.

Has participated in another investigational study involving any investigational product.

Currently enrolled or intends to participate in another clinical trial

Has previously participated in an investigational study involving LNP's.

Has a history of hypersensitivity or severe allergic reaction to any previous vaccines.

Chronic use of any medications that may be associated with impaired immune responsiveness

Anticipating the need for immunosuppressive treatment within the next 6 months.

Received immunoglobulins and/or any blood or blood products within the last 6 months.

Has any blood dyscrasias or significant disorder of coagulation.

Has any chronic liver disease, including fatty liver.

Has a history of alcohol abuse or other recreational drug use within 6 months of study vaccination.

Has a positive test result for drugs of abuse at screening or before first vaccination.

Has any abnormality or body part that would interfere with the ability to observe ocular reactions.

Plans to receive a licensed, inactivated vaccine within 2 weeks before or after each vaccination.

Plans to receive a licensed, inactivated vaccine within 2 weeks before or after each vaccination.

Receipt of any other 2019-nCoV or other experimental coronavirus vaccine at any time

Receipt of any other SARS-CoV-2 or other experimental coronavirus vaccine at any time.

Known contact of anyone known to have 2019-nCoV infection within 2 weeks prior to registration.

Close contact of anyone known to have SARS-CoV-2 infection within 30 days prior to registration.

History of COVID-19 diagnosis

On current treatment with investigational agents for prophylaxis of COVID-19

Has traveled to China within 30 days before first vaccination.

Current use of any medications within 7 days prior to vaccination.

The subject must agree to refrain from donating blood or plasma during the study.

Plan to travel outside the US through 28 days after the 2nd vaccination.

Reside in a nursing home or other skilled nursing facility or have a requirement for nursing care.

Non-smoker

For subjects >=56 years of age, history of chronic smoking within the prior year.

For subjects >=56 years of age, current smoking or vaping.

For subjects >=56 years of age, currently working with high risk of exposure to SARS-CoV-2

We Vis 4 02 09 112

me me A
me me

Hematology
 We e hematology tests pe o med?
 I No eason not done

I No reason not done

10 he specify

Blood collection date on hematology

☐ No
 ☐ es
 ☐ N/A

Subject unable o comply
 Subject e usual
 Clin c o
 Investigato decis on
 COVID- 9 pandem c
 *Add tional Options sted Be ow

[illegible]

Chemistry
 We e chemistry tes a pe o med?
 | No reason not done

1. No reason not done

LObe: spiky

Blood collection date, chemistry

☐ No ☐ es ☐ N/A

Subject unable o comply
Subject e usal
Cline o
Investigato decis on
COVID- 9 pandem c
*Add tional Options sted Be ow

[illegible]

Was a pregnancy test performed?
☐ Yes ☐ No ☐ Reason not done

I. No reason not done

I O he specify

1. One sp. only

Is specimen type

Specimen collection date

Specimen c

Serology
 Were serology tests performed?
 | No, reason not done

I. No reason not done

I O he specify

Blood collection date, season, year

Blood collection

H V antibody

HCV antibody

Urine Drug Screen
Was urine collected for drug screening?
☐ Yes, screen not done

Was urine collected or drug screening done?

I No reason not done

I O he specify

Specimen collection date

Did the subject use alcohol, an anesthetic, barbiturates, benzodiazepines, cocaine, methadone, marijuana, opiates, phenothiazines, and/or psychotropics?

☐ No
 ☒ es
 ☐ N/A

Subject unable to comply
 Subject unable
 Clinician
 Investigator decision
 COVID-19 pandemic
 *Additional Options listed Below

Subject unable to comply
Subject is usual
Clinical
Investigator decision
COVID-19 pandemic
*Additional Options listed Below

☐ No ☐ es ☐ NA
 Subject unable to comply
 Subject unable
 Clinician
 investigator decision
 COVID-19 pandemic
 *Additional Options listed Below

Additional Selection Options for LLR

If No reason not done
Other
Hemoglobin units
mmol/L
g/dL
L/L
seconds
Hemoglobin action taken
NA - Not applicable

Medical History (MHD)

200 2 403

Any medical history?									
M	m	a	s	T	a	a	a	a	a
2									
3									
4									
5									
6									
7									
8									
9									
0									
2									
3									
4									
5									
6									
7									
8									
9									
20									
2									
22									
23									
24									
25									
26									
27									
28									
29									
30									

No 49

Additional Selection Options for MHD

Form number (key file d)

1
2
3

5
6
7
8
9
10
11
12
13
14
15

We Visited 20,000 May 2000

[illegible][illegible]

Additional Selection Options for PE1

If No reason not done

Other

Body system 1

HNT - HEENT

LYM - Lymph nodes

MSC - Musculoskeletal

NEC - Neck

NEU - Neurological

PLM - Pulmonary chest

SKN - Skin

If yes AE number 1

6

7

8

9

10

11

12

13

1

15

16

17

18

19

20

21

22

23

2

25

26

27

28

29

30

31

32

33

3

35

36

37

38

39

0

1

2

3

5

6

7

8

9

50

If yes so icted AE 1

Fatigue

Myalgia

Arthralgia

Nausea

Fever

Chills

WBC

Hemoglobin

Platelets

ALT

AST

ALP

Bilirubin (to all)

Creatinine

PT

PTT

Vitals
Was weight assessed at this visit?
I No reason not done

Was v

Eligibility
Did the participant meet a l e g i b i l i t y

Did the pa
C. to le

C te ion not met 4

a c e a we e me bu he p ocedu e was no pe o med nd ca e he eason
ime comm tent

Other _____
 I Other specify _____
Leukapheresis Procedure
 Was leukapheresis performed?

Was leukaphe es a pe o med?

Stop time
 Volume collected
 Were there any complications

Additional Selection Options for VD1

- If No specify reason
 - Temporarily out of area
 - Subject target
 - Site decision error
 - COVID-19 pandemic
 - Other
- If No specify reason
 - Investigator decision
 - Other
- If No reason not done
 - Other
- Criterion not met 1
 - No use of blood thinners, aspirin, NSAIDs, at least 5 days before the leukapheresis procedure
 - Enrollment in cohorts 2, 3, 5 or 6 and completed the 2-dose vaccination series

We Ve s 02 27Apr 26

Q: We e vital signs assessed at h a visit ?

I O he specify

Assessme Time 24-hour c ock)	Tem e a e s	Tem e a e)	Tem e a e)	se bee s m mte)	s mmHg)	ess e mmHg)	as mmHg)	ess e
[] hh mm)	☐ ah enhit ☐ C esus	[] xxx x)	[] xx x)	[] xxx)	[] xxx)	[] xxx)	[] xxx)	

We e height and weight assessed at this visit?
I No reason not done

1 Other species

Assessme T me We s We s) Wo k ams) e s e s e me e s)

[] hh mm) [] ounds Klog ams [] xxx x) lb [] xxx x) kg [] inches Cent mete s [] xx x) n [] xxx x) cm

BVI

dsMMyyyy

No es

Sub ect unab e to comply
 Sub ect e usal
 C n c e o
 Investigato dec s on
 COV D- 9 pandemic
 *Add sional Opt ons sted Below

A screenshot of a Windows command prompt window. The title bar shows the text "No es". The command prompt displays the following text:

```
Sub ect unab e to comply
Sub ect e usal
CIn ce o
Investigato decs on
COV D- 9 pandemic
*Additional Opt ons sted Below
```

xxx,xx kg m²

Additional Selection Options for VS1

If No reason not done
Other

26

1

1

spontaneous abor on m date age s b h o he appeu c abo on comp e an AE SAE o m

nd cou e he sou ce o n o ma on may check es o mo e han onej

Mathe
am ly memba
hysic an med cal cha t
O he
I es speed y

Maternal Outcome

End o p agnancy weight	Date o end o p agnancy weight dMMMyyyyj	Date o se a n y Exact date Day only unknown Day and month unknown Day month and yes unknown *	Weight on bi ounds K/kg ams	Weight (lb) xxx xj lb	Weight (kg) xxx xj kg
------------------------	--	---	--------------------------------	---------------------------	--------------------------

Labor, Delivery, and Post Partum Information

Did the subject exper once any o he maten nat comp cat one used du ng abo del ve y o postpa tum?

es comp e e an AAdv se Eveni Se ou AAdv se Eveni o m as app up a e

Ab upho placenta Ec ampia GBS-posi ve

Abno mal bleedng hemo tage Eme gency Cesa ean section due o etal dist esu Olyhyal ams os

Anaphylaxis Endomet it s scem a p evia

Bacte emia e at dist esu olyhyd amnos

Cho loarm on is eve > 00.4 o 38.0 C e-ec ampia

Congulat on dnu de s Gestational diabetes agnancy reduced type tens on

Cr d p placen site m abo

Did the subject exper once any other ma e nat complications du ng th a p agnancy?

es comp e e an AAdv se Eveni Se ou AAdv se Eveni o m as app up a e

Was the e any etal it es du ng labo and del ve y?

es comp e e an AAdv se Eveni o m

Neonatal Outcome Live Birth and Still Birth Only

De a o l ve bi th o st b bi th

De lve y

Sex

n act a d ges at onal age at l ve bi th o at b bi th

Size o ges a l onal age

Bl th weight	ounds K/kg ams	xx xj lb	xx xj kg
eng th	inches Cent me e s	xx xj in	xx xj cm
Ortal occipit al ci curv e ence (OC)	inches Cent me e s	xx xj in	xx xj cm

Apge into e minu e leave blank o S i t B i th

Apge into e S minu es leave blank o S i t B i th

Co d par

Congenit al anomalies

es comp e e an AAdv se Eveni o m

One Month Follow Up Live Birth Only

Has he n ant been diagnosed w th any congen ital anomalies since bi th? No p ev ou s y app ed abovej

es comp e e a Se ou AAdv se Eveni o m

Has he n ant been i o hospi a lized? Does no nclude we ch d v s d j

I es speed y

One or Two Month Follow Up Still Birth Only

Was the n an on opy?

I es was an etio ogy o he st b bi th dnt ied?

I es speed y

Pregnancy Outcome Spontaneous, Elective or Therapeutic Abortion Only

Was e o be mision

etal ges at onal age at te m nat on

Any abno mal ty in p duct on concept on?

I es speed y

Reason o the spont c abo t on

Comments

Pregnancy Outcome 1 (X1D)

We Ve s 0 2 eto2

ve bi th (Spontaneous abo son misca sage <20 wks) Still bi th (= 20 weeks) E act ve abo son he appeu c abo t on
No es
No es
No es

No es Unknown N A

No es Unknown

No es Unknown N A

dMMMyyyyj

Vaginal Cesa ean section

Male ema e

xj weeks and xj days

SGA AGA GA

xj

xj

No es

No es Unknown

No es Unknown

No es Unknown

No es Unknown

dMMMyyyyj

xj weeks and xj days

No es Unknown N A

Male nat cond t on disease etal cond t on disease

We have 0.2 g of 20

[illegible]

Pregnancy Outcome 3 (X3D)

We Vis 0 2 eh25

[illegible][illegible]

[illegible][illegible]

Additional Selection Options for XPD

type of substance 1
Benzococaine
Cocaine
Codeine
Dextromethorphan (DXM)
Fentanyl and analogs
Flunitrazepam
GHB
Hashish
Heroin
Hydrocodone Bitartrate Hydromorphone
Inhalants
K2/Spice (synthetic marijuana)
Ketamine
LSD
Marijuana
MDMA
Meprobamate
Mescaline
Methadone
Methamphetamine
Methylphenidate
Morphine
Opium
Oxycodone HCL
Oxycodone
PCP and analogs
Propoxyphene
Psilocybin
Salvia divinorum
Sleep medication
Tobacco
Substance route 1
Subcutaneous
Substance unit 1
Gram
Joint
Liter
Milligram
Ounce
Pack
Standard drink
Substance frequency 1
Every 2 months
1 time per week
2 times per week
3 times per week
4 times per week
5 times per week
6 times per week

Adverse Event (ZAE)

a me A
 Advise event
 His date
 End date
 Associated with dose number

 Save i y
 I Save a on
 Re a onship to study i eatment
 I Not Re a ed: the event is e ated to

 I Not Re a ed: speed y al e native et o gy
 What ac ion was taken with the s ufy i eatment ?

 Did the advise se event cause the sub ect to be d icon trused om he study?
 Outcome

 s the event an Advise Event o Spec al n e AES?
 es: n e ca a ce ago y o AES be ow
 Is the event Medically At oned Advise se Event (MAAE)?
 Is he event a New Onset Ch onic Medical Cond ion (NOCMI)?
 s this event an "Unan icipated" ob em?

Serious Adverse Events
 s the advise se event an: aet?
 Is es: date event became an SAE
 Is he advise se event associated with a congen tal anomaly o bi th de ect?
 D d the advise se event: esult in pa s ent o signi icant disability o ospitality?
 D d the advise se event: esult in death?
 D d the advise se event: esult in in itial o p o onged hospitalization o he sub ect?
 Is he advise se event i e e eaten ryo?
 Is he advise se event a medical y impo tant event not covered by other "he loss" c i e a?

Hating Criteria
 s the event h a b i l i n the op n o n he s to invest gate: this event should be e evaluated o poss b e correct, but on the basis of the hating i e i k o he g up: coh o 1 o s ufy
 Conclusions

[illegible]

Additional Selection Options for ZAE

AE Number (key to d)

- 1
- 2
- 3
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 1
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 2
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 3
- 35
- 36
- 37
- 38
- 39
- 0
- 1
- 2
- 3
- 5
- 6
- 7
- 8
- 9
- 50

What action was taken with the study treatment?

NA = Not applicable

We have 03.0.122

FDA-CBER-2022-1614-3223524

Additional Selection Options for ZLR

Parameter (key field)
Hemoglobin
Alanine Aminotransferase
Aspartate Aminotransferase
Creatinine
eGFR
Blood Urea Nitrogen
Potassium
Magnesium
Total Bilirubin
White Blood Cells
Platelets
Alkaline Phosphatase
Lipase
Prothrombin Time
Partial Thromboplastin Time
Hematocrit
Units: g/L
mmol/L
10⁹/L
U/L
seconds
%

Solicited Local Events (ZRL)

We Vis 0 27Apr26

FDA-CBER-2022-1614-3223526 41

Additional Selection Options for ZRL

Dose Number (key field)

1
2
3

5
6
7
8
9

10
Period Number (key field)

1
2
3

5
6
7
8
9
10

[illegible]

Additional Selection Options for ZRS

Dose Number (key field)

1
2
3

5
6
7
8
9

10
Period Number (key field)

1
2
3

5
6
7
8
9
10

00:28:40:00

Grade 3 Systemic Reactions Within 7 Days After Administration

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

No

2

3

4

5

Additional Options

Selected Below

Comment

Additional Selection Options for ZSA

Dose Number (key field)

1
2
3

5
6
7
8
9

Period Number (key field)

1
2
3

5
6
7
8
9
10

AE or med cal history 1

6
7
8
9
10
11
12
13
1
15
16
17
18
19
20
21
22
23

2
25
26
27
28
29
30
31
32
33
3
35
36
37
38
39

0
1
2
3

5
6
7
8
9

50
Medical History
Other

Visit 1

Baseline Assessment (prior to treatment administration)

Assessment of Systemic Symptoms

Arthralgia/joint pain

None
Mild
Moderate
Severe
Not Done

Chills

None
Mild
Moderate
Severe
Not Done

Fatigue

None
Mild
Moderate
Severe
Not Done

Headache

None
Mild
Moderate
Severe
Not Done

Myalgia

None
Mild
Moderate
Severe
Not Done

Nausea

None
Mild
Moderate
Severe
Not Done

Treatment Administration Information

Review the assessment number as also used on the study protocol. Do not use the first name on page.

Assessment administration site

Time of administration (24-hour clock)

Time of individual who administered the treatment

Post Administration Assessment

Time of assessment (24-hour clock)

Assessment of adverse events (AEs) from 60 minutes after administration

Assessment of Systemic Reactions

Arthralgia/joint pain

None
Mild
Moderate
Severe
Not Done

No

Yes

Chills

None
Mild
Moderate
Severe
Not Done

No

Yes

Fatigue (tiredness)

None
Mild
Moderate
Severe
Not Done

No

Yes

Headache

None
Mild
Moderate
Severe
Not Done

No

Yes

Myalgia (Body aches Muscular pain)

None
Mild
Moderate
Severe
Not Done

No

Yes

Nausea

None
Mild
Moderate
Severe
Not Done

No

Yes

Assessment of Local Reactions

Site

None
Mild
Moderate
Severe
Not Done

Injection site (Hematoma, Edema, Swelling)

None
Mild
Moderate
Severe
Not Done

Injection site (Redness)

None
Mild
Moderate
Severe
Not Done

Injection site (Pain at injection site measured in mm)

Not Done

Injection site (Redness at injection site measured in mm)

Not Done

Injection site (Swelling at injection site measured in mm)

Not Done

00MM/yyyy

Right arm

Left arm

Measure

Additional Selection Options for ZVR

Arthralgia AE or MH

6
7
8
9
10
11
12
13
1
15
16
17
18
19
20
21
22
23
2
25
26
27
28
29
30
31
32
33
3
35
36
37
38
39
0
1
2
3

5
6
7
8
9
50
Medical History
Other

